Sodium Hydroxide → 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamide

HRID 1091664ノート

反応式

HRID 1091664 の反応式
[S:1]1[C:5]2[CH:6]=[CH:7][CH:8]=[CH:9][C:4]=2[NH:3][C:2]1=[C:10]([C:13]1[N:18]=[CH:17][CH:16]=[CH:15][N:14]=1)[C:11]#[N:12].[OH-:19].[Na+]>S(=O)(=O)(O)O>[S:1]1[C:5]2[CH:6]=[CH:7][CH:8]=[CH:9][C:4]=2[NH:3][C:2]1=[C:10]([C:13]1[N:14]=[CH:15][CH:16]=[CH:17][N:18]=1)[C:11]([NH2:12])=[O:19]

参加物

4

反応物 2

HCID 14798Sodium HydroxideHCID 66593501HCID 66593501、化合物

生成物 1

HCID 665933542-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamide収率 40%

試薬・触媒・溶媒 1

HCID 1118Sulfuric Acid溶媒

実験手順

2-[Benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetonitrile (0.1 g, 0.39 mmol) was dissolved in concentrated sulfuric acid (2 mL) and stirred at room temperature for 5 hr. The mixture was cooled to 0° C., poured over ice, and neutralized with 50% aqueous sodium hydroxide. The precipitate that formed was collected by filtration and purified by reverse phase preparative HPLC to give 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamide (42 mg, 40% yield) as a yellow solid.

後処理

  1. temperatureThe mixture was cooled to 0° C.
  2. additionpoured over ice
  3. customThe precipitate that formed
  4. filtrationwas collected by filtration
  5. custompurified by reverse phase preparative HPLC

出典と根拠

ORDレコード
ord-abb47f7e7e4341318753fd42aa9fb1af
出典データセット
uspto-grants-2012_03
特許番号
US08129396B2

反応ノート

読み込み中…